• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

NHS - Articles and news items

Pfizer’s breast cancer drug too expensive for NHS

Industry news / 3 February 2017 / Niamh Marriott, Digital Editor

NICE has today published draft guidance which does not recommend Pfizer’s breast cancer drug palbociclib for routine funding on the NHS…

NICE approves former CDF kidney cancer drug for NHS use

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma…

NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use

Industry news / 29 December 2016 / Niamh Louise Marriott, Digital Editor

Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should…

NICE approves three quarters of CDF drugs for routine NHS use

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), […]

Infirst’s treatment for chronic wounds now available on NHS

Industry news / 30 September 2016 / Niamh Louise Marriott, Digital Content Producer

Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds, venous leg ulcers, by 75% compared to standard care…

NICE recommends Novartis’ ankylosing spondylitis drug

Industry news / 29 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy…

NICE says Bayer’s liver cancer drug is not cost-effective

Industry news / 24 August 2016 / The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available…

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

New draft guidance advises that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective…

NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)

Industry news / 30 March 2016 / Victoria White

Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1…

MenB vaccine Bexsero might see private uptake in the UK

Industry news / 9 March 2016 / GlobalData

The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves…

Eisai criticises NHSE for further delaying access to cancer treatments

Industry news / 26 February 2016 / Victoria White

New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund…

Public Accounts Committee publishes report on the Cancer Drugs Fund

Industry news / 5 February 2016 / Victoria White

A Public Accounts Committee has released its recommendations for the reform of the Cancer Drugs Fund…